Advertisement
Screener

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Share-based Payment Arrangement, Expensed and Capitalized, Amount

2.3 / 5 stars · 27/60 Roast Me

IOVANCE BIOTHERAPEUTICS, INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $11.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Expensed and Capitalized, Amount

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-08-06

  • IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-06-30 was $11.73M, a 21.48% decline year-over-year.
  • IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-03-31 was $11.27M, a 50.82% decline year-over-year.
  • IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-12-31 was $11.82M, a 61.85% decline year-over-year.
  • IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-09-30 was $11.90M, a 61.62% decline year-over-year.
  • IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2025 was $61.58M, a 43.83% decline from fiscal 2024.
  • IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2024 was $109.62M, a 75.05% increase from fiscal 2023.
  • IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $62.63M, a 25.47% decline from fiscal 2022.
  • IOVANCE BIOTHERAPEUTICS, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2022 was $84.02M, a 20.44% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Expensed and Capitalized, Amount 3 monthShare-based Payment Arrangement, Expensed and Capitalized, Amount 3 month as first filedShare-based Payment Arrangement, Expensed and Capitalized, Amount 6 monthShare-based Payment Arrangement, Expensed and Capitalized, Amount 9 monthShare-based Payment Arrangement, Expensed and Capitalized, Amount 9 month as first filedShare-based Payment Arrangement, Expensed and Capitalized, Amount 12 monthShare-based Payment Arrangement, Expensed and Capitalized, Amount 12 month as first filed
2026-06-30$11.73M
10-Q · filed 2026-08-06
$23.00M
10-Q · filed 2026-08-06
$34.82M
derived: sum of 3 quarters · filed 2026-08-06
$46.72M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$11.27M
10-Q · filed 2026-05-07
$23.09M
derived: sum of 2 quarters · filed 2026-05-07
$34.99M
derived: sum of 3 quarters · filed 2026-05-07
$49.93M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$11.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$23.72M
derived: sum of 2 quarters · filed 2026-02-24
$38.66M
derived: sum of 3 quarters · filed 2026-08-06
$61.58M
10-K · filed 2026-02-24
2025-09-30$11.90M
10-Q · filed 2025-11-06
$26.84M
derived: sum of 2 quarters · filed 2026-08-06
$49.76M
10-Q · filed 2025-11-06
$80.73M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$14.94M
10-Q · filed 2026-08-06
$37.86M
10-Q · filed 2026-08-06
$68.83M
derived: sum of 3 quarters · filed 2026-08-06
$99.84M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$22.91M
10-Q · filed 2026-05-07
$53.89M
derived: sum of 2 quarters · filed 2026-05-07
$84.89M
derived: sum of 3 quarters · filed 2026-05-07
$115.36M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$30.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$61.98M
derived: sum of 2 quarters · filed 2026-02-24
$92.44M
derived: sum of 3 quarters · filed 2026-02-24
$109.62M
10-K · filed 2026-02-24
2024-09-30$31.01M
10-Q · filed 2025-11-06
$61.47M
derived: sum of 2 quarters · filed 2025-11-06
$78.65M
10-Q · filed 2025-11-06
$93.05M
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30$30.47M
10-Q · filed 2025-08-07
$47.64M
10-Q · filed 2025-08-07
$62.04M
derived: sum of 3 quarters · filed 2026-02-24
$77.86M
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31$17.18M
10-Q · filed 2025-05-08
$31.58M
derived: sum of 2 quarters · filed 2026-02-24
$47.40M
derived: sum of 3 quarters · filed 2026-02-24
$64.14M
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31$14.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$30.22M
derived: sum of 2 quarters · filed 2026-02-24
$46.96M
derived: sum of 3 quarters · filed 2026-02-24
$62.63M
10-K · filed 2026-02-24
2023-09-30$15.82M
10-Q · filed 2024-11-07
$32.56M
derived: sum of 2 quarters · filed 2024-11-07
$48.23M
10-Q · filed 2024-11-07
$67.73M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$16.74M
10-Q · filed 2024-08-08
$32.41M
10-Q · filed 2024-08-08
$51.91M
derived: sum of 3 quarters · filed 2025-02-27
$71.69M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$15.66M
10-Q · filed 2024-05-09
$35.17M
derived: sum of 2 quarters · filed 2025-02-27
$54.95M
derived: sum of 3 quarters · filed 2025-02-27
$77.42M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$19.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$39.29M
derived: sum of 2 quarters · filed 2025-02-27
$61.76M
derived: sum of 3 quarters · filed 2025-02-27
$84.02M
10-K · filed 2025-02-27
2022-09-30$19.78M
10-Q · filed 2023-11-07
$42.25M
derived: sum of 2 quarters · filed 2023-11-07
$64.51M
10-Q · filed 2023-11-07
$83.62M
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30$22.47M
10-Q · filed 2023-08-08
$44.73M
10-Q · filed 2023-08-08
$63.84M
derived: sum of 3 quarters · filed 2024-02-28
$83.14M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31$22.27M
10-Q · filed 2023-05-10
$41.37M
derived: sum of 2 quarters · filed 2024-02-28
$60.67M
derived: sum of 3 quarters · filed 2024-02-28
$75.09M
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31$19.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
$38.41M
derived: sum of 2 quarters · filed 2024-02-28
$52.82M
derived: sum of 3 quarters · filed 2024-02-28
$69.77M
10-K · filed 2024-02-28
2021-09-30$19.31M
10-Q · filed 2022-11-03
$33.72M
derived: sum of 2 quarters · filed 2022-11-03
$50.66M
10-Q · filed 2022-11-03
$60.89M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$14.41M
10-Q · filed 2022-08-04
$31.36M
10-Q · filed 2022-08-04
$41.59M
derived: sum of 3 quarters · filed 2023-02-28
$52.29M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$16.94M
10-Q · filed 2022-05-05
$27.17M
derived: sum of 2 quarters · filed 2023-02-28
$37.88M
derived: sum of 3 quarters · filed 2023-02-28
$48.42M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$10.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$20.94M
derived: sum of 2 quarters · filed 2023-02-28
$31.48M
derived: sum of 3 quarters · filed 2023-02-28
$40.89M
10-K · filed 2023-02-28
2020-09-30$10.71M
10-Q · filed 2021-11-04
$21.24M
derived: sum of 2 quarters · filed 2021-11-04
$30.66M
10-Q · filed 2021-11-04
$36.06M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30$10.54M
10-Q · filed 2021-08-05
$19.95M
10-Q · filed 2021-08-05
$25.36M
derived: sum of 3 quarters · filed 2022-02-24
$31.95M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31$9.41M
10-Q · filed 2021-05-06
$14.82M
derived: sum of 2 quarters · filed 2022-02-24
$21.42M
derived: sum of 3 quarters · filed 2022-02-24
$27.84M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31$5.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$12.01M
derived: sum of 2 quarters · filed 2022-02-24
$18.43M
derived: sum of 3 quarters · filed 2022-02-24
$24.28M
10-K · filed 2022-02-24
2019-09-30$6.60M
10-Q · filed 2020-11-05
$13.02M
derived: sum of 2 quarters · filed 2020-11-05
$18.87M
10-Q · filed 2020-11-05
$24.05M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$6.43M
10-Q · filed 2020-08-06
$12.27M
10-Q · filed 2020-08-06
$17.46M
derived: sum of 3 quarters · filed 2021-02-25
$22.97M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$5.85M
10-Q · filed 2020-05-05
$11.03M
derived: sum of 2 quarters · filed 2021-02-25
$16.55M
derived: sum of 3 quarters · filed 2021-02-25
$21.77M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$5.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$10.70M
derived: sum of 2 quarters · filed 2021-02-25
$15.92M
derived: sum of 3 quarters · filed 2021-02-25
$20.03M
10-K · filed 2021-02-25
$20.03K
10-K · filed 2019-02-28
2018-09-30$5.52M
10-Q · filed 2019-11-04
$10.74M
derived: sum of 2 quarters · filed 2019-11-04
$14.84M
10-Q · filed 2019-11-04
$17.60M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$5.22M
10-Q · filed 2019-08-01
$9.33M
10-Q · filed 2019-08-01
$12.09M
derived: sum of 3 quarters · filed 2020-02-25
$14.71M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31$4.10M
10-Q · filed 2019-05-07
$6.86M
derived: sum of 2 quarters · filed 2020-02-25
$9.48M
derived: sum of 3 quarters · filed 2020-02-25
$12.78M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31$2.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$5.38M
derived: sum of 2 quarters · filed 2020-02-25
$8.67M
derived: sum of 3 quarters · filed 2020-02-25
$11.97M
10-K · filed 2020-02-25
2017-09-30$2.62M
10-Q · filed 2018-11-06
$5.91M
derived: sum of 2 quarters · filed 2018-11-06
$9.21M
10-Q · filed 2018-11-06
-$6.55M
derived: sum of 4 quarters · filed 2019-02-28
2017-06-30$3.29M
10-Q · filed 2018-08-07
$6.59M
10-Q · filed 2018-08-07
-$9.17M
derived: sum of 3 quarters · filed 2019-02-28
-$528.10K
derived: sum of 4 quarters · filed 2019-02-28
2017-03-31$3.30M
10-Q · filed 2018-05-10
-$12.47M
derived: sum of 2 quarters · filed 2019-02-28
-$3.82M
derived: sum of 3 quarters · filed 2019-02-28
$1.54M
derived: sum of 4 quarters · filed 2019-02-28
2016-12-31-$15.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28
-$7.12M
derived: sum of 2 quarters · filed 2019-02-28
-$1.76M
derived: sum of 3 quarters · filed 2019-02-28
$18.90K
10-K · filed 2019-02-28
$18.90M
10-K · filed 2017-03-09
2016-09-30$8.64M
10-Q · filed 2017-11-02
$14.00M
derived: sum of 2 quarters · filed 2017-11-02
$15.78M
10-Q · filed 2017-11-02
$18.53M
derived: sum of 4 quarters · filed 2018-03-12
2016-06-30$5.36M
10-Q · filed 2017-08-03
$7.14M
10-Q · filed 2017-08-03
$9.88M
derived: sum of 3 quarters · filed 2018-03-12
$12.27M
derived: sum of 4 quarters · filed 2018-03-12
2016-03-31$1.78M
10-Q · filed 2017-05-03
$4.52M
derived: sum of 2 quarters · filed 2018-03-12
$6.91M
derived: sum of 3 quarters · filed 2018-03-12
$8.84M
derived: sum of 4 quarters · filed 2018-03-12
2015-12-31$2.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
$5.13M
derived: sum of 2 quarters · filed 2018-03-12
$7.06M
derived: sum of 3 quarters · filed 2018-03-12
$8.52M
10-K · filed 2018-03-12
2015-09-30$2.39M
10-Q · filed 2016-11-04
$2.39M
10-Q · filed 2015-11-06
$4.31M
derived: sum of 2 quarters · filed 2016-11-04
$5.78M
10-Q · filed 2016-11-04
$5.78M
10-Q · filed 2015-11-06
$6.87M
derived: sum of 4 quarters · filed 2017-03-09
2015-06-30$1.92M
10-Q · filed 2016-08-09
$3.39M
10-Q · filed 2016-08-09
$4.48M
derived: sum of 3 quarters · filed 2017-03-09
$5.42M
derived: sum of 4 quarters · filed 2017-03-09
2015-03-31$1.47M
10-Q · filed 2016-05-09
$2.56M
derived: sum of 2 quarters · filed 2017-03-09
$3.50M
derived: sum of 3 quarters · filed 2017-03-09
2014-12-31$1.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09
$2.03M
derived: sum of 2 quarters · filed 2017-03-09
$3.81M
10-K · filed 2017-03-09
2014-09-30$940.00K
10-Q · filed 2015-11-06
$2.72M
10-Q · filed 2015-11-06
2013-12-31$2.75M
10-K · filed 2016-03-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B